Close

Anti-UL49 T cell receptor (W21), pCDTCR1 (TCR-YC1302)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

One epitope, amino acids 49-57 of virion protein 22 (VP22), encoded by gene UL49, is immunodominant in terms of cell number and population prevalence when referenced to the current integrated data set. Amongst persons with the restricting HLA B*0702 allele, about 50% have CD8 (+) lymphocytes in peripheral blood at a level high enough to detect with direct staining with tetramers of HLA B*0702 and the peptide (sequence RPRGEVRFL). EC50 value of TCR clone W21 is 0.327 μM for cytotoxicity.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • UL49
  • Target Species
  • HHV2
  • Epitope
  • RPRGEVRFL
  • Format
  • Non-Modified TCR
  • Allele
  • HLA-B*07:02
  • Vector Name
  • pCDTCR1
  • Vector Length
  • ~ 8 kb
  • Vector Type
  • Lentiviral vector
  • TCR Clone
  • W21
  • Host Species
  • Human

Target

  • Introduction
  • Tegument protein that plays different roles during the time course of infection. Participates in both the accumulation of viral mRNAs and viral protein translation at late time of infection. Modulates the RNase activity of the virion host shutoff protein UL41 probably to ensure necessary levels of key cellular mRNAs and proteins. Plays a role in microtubule reorganization that occurs after viral infection by stabilizing microtubule network.

Customer Reviews and Q&As

There are currently no customer reviews or questions for Human anti-UL49 T cell receptor (W21), pCDTCR1 (TCR-YC1302). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.